Psychiatry · ADHDTrial Updateclinicalmid-term

Study on CBT-I Efficacy in Adolescents with ADHD Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 6:30:51 PM

Assessment confidence: 83% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The initiation of this study on CBT-I for adolescents with ADHD is significant as it addresses a critical gap in treatment options for this population. Successful outcomes could lead to new therapeutic protocols and enhance market opportunities for sleep-related interventions in ADHD. Regulatory context from MHRA (Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis) supports the near-term read. Assessment grounded in 19 ranked evidence items (17 high-relevance).

Strategic Assessment

If successful, this could lead to new treatment protocols and market opportunities for therapies targeting sleep disturbances in ADHD. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In Psychiatry · ADHD, 3 regulatory and 4 competitive items passed relevance filtering for ADHD treatment protocols.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study.

Regulatory Outlook

Regulatory risk is concentrated around Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. Positive results may influence future regulatory approvals for CBT-I applications in ADHD, impacting labeling and compliance requirements for new treatments.

Key Risks

Elevated medium regulatory exposure for ADHD treatment protocols could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates efficacy, it could open new revenue streams for companies developing therapies targeting sleep disturbances in ADHD, potentially increasing market share in this niche area.
Lead sponsor: Brii Biosciences Limited. Collaborators: Vir Biotechnology, Inc., VBI Vaccines Inc..
If successful, this could lead to new treatment protocols and market opportunities for therapies targeting sleep disturbances in ADHD.

What Would Change This Assessment

This becomes more urgent if Monitor results from this trial and any subsequent studies on CBT-I in ADHD populations.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Nipocalimab (Imaavy) authorised to treat adults and adolescents with generalised myasthenia gravis
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: PALSONIFY
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Efficacy of Gamified Blended Mindfulness Program to Reduce Burnout, Stress, and Anxiety in Nursing Students: A Randomized Controlled Trial
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT
Humanexa Signalsmedium relevance
Moderate corpus alignment
Nanovaccines Show Superior Efficacy Over Ampicillin in Preventing Neonatal Listeriosis
Humanexa Signalsmedium relevance
Moderate corpus alignment

Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of crisaborole ointment combined with 308-nm excimer laser in the treatment of non-segmental vitiligo: a randomized, intra-patient left-right controlled study protocol.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ADHD treatment protocols

Commercial impact

medium

If the trial demonstrates efficacy, it could open new revenue streams for companies developing therapies targeting sleep disturbances in ADHD, potentially increasing market share in this niche area.

Regulatory impact

medium

Positive results may influence future regulatory approvals for CBT-I applications in ADHD, impacting labeling and compliance requirements for new treatments.

What to watch

Monitor results from this trial and any subsequent studies on CBT-I in ADHD populations.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.